A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Tilapertin (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Study 165
- Sponsors Amgen
- 15 Jun 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 16 Jul 2012 Additional trial location (Czech Republic) addedd as reported by ClinicalTrials.gov.
- 23 Jun 2012 Additional trial location identified as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History